Merkel Cell Carcinoma

P2, N=18, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027

Distinguishing FA with HTT-like morphology from genuine HTT might have therapeutic and prognostic (follow-up) implications, based on the benign nature of the former and the low-risk biology of the latter. However, the full biological spectrum of this FA subtype and its genetic background need more delineation in larger future studies with long follow-up.

We highlight an integrated diagnostic framework that combines morphology, broad immunohistochemical panels, and molecular testing. Accurate recognition of these tumors is essential, as correct classification directly informs prognosis and therapeutic decision-making.

We herein report a case of challenging CDS diagnosed by genomic profiling, with weak, focal cytoplasmic WT-1 positivity, positive staining for CD56, CD138 (subset), and CD4 (subset). This case highlights the challenges involved in evaluating cutaneous small round blue cell tumors based on morphology and immunohistochemistry alone, especially in the presence of an atypical immunophenotype.

P1/2, N=19, Active, not recruiting, Melanoma and Skin Cancer Trials Limited | Recruiting --> Active, not recruiting | Trial completion date: Jul 2027 --> Dec 2027 | Trial primary completion date: Jul 2027 --> Dec 2026

P=N/A, N=12, Active, not recruiting, AdventHealth Translational Research Institute | Recruiting --> Active, not recruiting | N=20 --> 12 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Aug 2025

P1/2, N=31, Not yet recruiting, University of Wisconsin, Madison

We provide the first functional evidence of the pleiotropic tumor suppressor role of hsa-miR-34a-5p in VN-MCC.

P1/2, N=132, Recruiting, Mayo Clinic | N=36 --> 132 | Trial completion date: Feb 2026 --> Mar 2028 | Trial primary completion date: Feb 2025 --> Mar 2028

Interestingly, MCPyV positivity was significantly correlated with female sex but not with age or specific MPN genetic mutations, except for myeloproliferative leukemia virus oncogene (MPL) mutations. These findings suggest a potential association between MCPyV and MPNs, particularly ET, and support further investigation into the role of human polyomavirus in megakaryocytic lineage biology.

All pituitary tumors stained as expected. These findings demonstrate that T-PIT and PIT-1 are highly specific for pituitary origin, while SF-1 shows limited off-target expression in certain high-grade sinonasal tumors with chromatin remodeling (e.g., NUT carcinoma and SMARCB1-deficient carcinoma).

P2, N=100, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Oct 2026 | Trial primary completion date: Dec 2025 --> Oct 2026